vs

Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and UTAH MEDICAL PRODUCTS INC (UTMD). Click either name above to swap in a different company.

SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $9.0M, roughly 1.4× UTAH MEDICAL PRODUCTS INC). UTAH MEDICAL PRODUCTS INC runs the higher net margin — 28.4% vs 1.3%, a 27.1% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -1.2%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -10.7%).

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites...

SLSN vs UTMD — Head-to-Head

Bigger by revenue
SLSN
SLSN
1.4× larger
SLSN
$12.5M
$9.0M
UTMD
Growing faster (revenue YoY)
SLSN
SLSN
+0.6% gap
SLSN
-0.7%
-1.2%
UTMD
Higher net margin
UTMD
UTMD
27.1% more per $
UTMD
28.4%
1.3%
SLSN
Faster 2-yr revenue CAGR
SLSN
SLSN
Annualised
SLSN
12.5%
-10.7%
UTMD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SLSN
SLSN
UTMD
UTMD
Revenue
$12.5M
$9.0M
Net Profit
$163.0K
$2.6M
Gross Margin
27.5%
58.2%
Operating Margin
1.5%
27.0%
Net Margin
1.3%
28.4%
Revenue YoY
-0.7%
-1.2%
Net Profit YoY
129.2%
-11.6%
EPS (diluted)
$0.00
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLSN
SLSN
UTMD
UTMD
Q4 25
$12.5M
$9.0M
Q3 25
$14.6M
$9.8M
Q2 25
$20.4M
$10.0M
Q1 25
$14.6M
$9.7M
Q4 24
$12.6M
$9.2M
Q3 24
$16.9M
$10.0M
Q2 24
$13.0M
$10.4M
Q1 24
$9.9M
$11.3M
Net Profit
SLSN
SLSN
UTMD
UTMD
Q4 25
$163.0K
$2.6M
Q3 25
$-1.1M
$2.6M
Q2 25
$2.7M
$3.0M
Q1 25
$80.0K
$3.0M
Q4 24
$-559.0K
$2.9M
Q3 24
$3.0M
$3.6M
Q2 24
$856.0K
$3.5M
Q1 24
$893.0K
$4.0M
Gross Margin
SLSN
SLSN
UTMD
UTMD
Q4 25
27.5%
58.2%
Q3 25
23.1%
57.1%
Q2 25
28.9%
56.2%
Q1 25
23.1%
57.0%
Q4 24
22.0%
58.1%
Q3 24
36.2%
58.0%
Q2 24
28.7%
60.1%
Q1 24
36.3%
59.7%
Operating Margin
SLSN
SLSN
UTMD
UTMD
Q4 25
1.5%
27.0%
Q3 25
-5.4%
26.6%
Q2 25
9.4%
32.1%
Q1 25
1.8%
32.5%
Q4 24
-1.8%
32.0%
Q3 24
19.0%
33.4%
Q2 24
8.0%
33.1%
Q1 24
11.3%
34.2%
Net Margin
SLSN
SLSN
UTMD
UTMD
Q4 25
1.3%
28.4%
Q3 25
-7.7%
26.8%
Q2 25
13.1%
30.6%
Q1 25
0.5%
31.3%
Q4 24
-4.4%
31.7%
Q3 24
18.1%
35.6%
Q2 24
6.6%
33.2%
Q1 24
9.0%
34.9%
EPS (diluted)
SLSN
SLSN
UTMD
UTMD
Q4 25
$0.00
$0.80
Q3 25
$-0.02
$0.82
Q2 25
$0.04
$0.94
Q1 25
$0.00
$0.92
Q4 24
$0.00
$0.86
Q3 24
$0.04
$1.03
Q2 24
$0.01
$0.98
Q1 24
$0.02
$1.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLSN
SLSN
UTMD
UTMD
Cash + ST InvestmentsLiquidity on hand
$1.3M
$85.8M
Total DebtLower is stronger
$225.0K
Stockholders' EquityBook value
$17.6M
$119.3M
Total Assets
$50.1M
$122.5M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLSN
SLSN
UTMD
UTMD
Q4 25
$1.3M
$85.8M
Q3 25
$429.0K
$84.3M
Q2 25
$4.1M
$82.2M
Q1 25
$1.8M
$83.3M
Q4 24
$1.4M
$83.0M
Q3 24
$2.9M
$88.5M
Q2 24
$2.4M
$89.2M
Q1 24
$2.0M
$93.8M
Total Debt
SLSN
SLSN
UTMD
UTMD
Q4 25
$225.0K
Q3 25
Q2 25
Q1 25
$269.0K
Q4 24
$282.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
SLSN
SLSN
UTMD
UTMD
Q4 25
$17.6M
$119.3M
Q3 25
$17.2M
$118.3M
Q2 25
$18.2M
$117.5M
Q1 25
$15.2M
$117.0M
Q4 24
$14.9M
$117.4M
Q3 24
$15.2M
$124.2M
Q2 24
$11.9M
$124.1M
Q1 24
$5.0M
$127.7M
Total Assets
SLSN
SLSN
UTMD
UTMD
Q4 25
$50.1M
$122.5M
Q3 25
$54.0M
$122.0M
Q2 25
$60.0M
$120.8M
Q1 25
$57.0M
$122.5M
Q4 24
$50.0M
$122.5M
Q3 24
$48.0M
$129.7M
Q2 24
$40.8M
$130.0M
Q1 24
$38.5M
$135.4M
Debt / Equity
SLSN
SLSN
UTMD
UTMD
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLSN
SLSN
UTMD
UTMD
Operating Cash FlowLast quarter
$1.8M
$3.5M
Free Cash FlowOCF − Capex
$3.4M
FCF MarginFCF / Revenue
37.2%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
11.16×
1.36×
TTM Free Cash FlowTrailing 4 quarters
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLSN
SLSN
UTMD
UTMD
Q4 25
$1.8M
$3.5M
Q3 25
$-2.5M
$3.9M
Q2 25
$-654.0K
$2.9M
Q1 25
$-7.2M
$4.5M
Q4 24
$2.2M
$2.9M
Q3 24
$4.2M
$3.9M
Q2 24
$-565.0K
$2.8M
Q1 24
$-3.9M
$5.3M
Free Cash Flow
SLSN
SLSN
UTMD
UTMD
Q4 25
$3.4M
Q3 25
$3.9M
Q2 25
$2.8M
Q1 25
$4.3M
Q4 24
$-404.0K
$2.9M
Q3 24
$2.8M
$3.8M
Q2 24
$-1.0M
$2.7M
Q1 24
$-3.9M
$5.3M
FCF Margin
SLSN
SLSN
UTMD
UTMD
Q4 25
37.2%
Q3 25
39.2%
Q2 25
28.4%
Q1 25
44.1%
Q4 24
-3.2%
32.0%
Q3 24
16.6%
37.7%
Q2 24
-8.0%
25.5%
Q1 24
-39.9%
46.3%
Capex Intensity
SLSN
SLSN
UTMD
UTMD
Q4 25
1.2%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
1.9%
Q4 24
20.6%
0.1%
Q3 24
8.3%
0.9%
Q2 24
3.7%
1.1%
Q1 24
0.9%
0.2%
Cash Conversion
SLSN
SLSN
UTMD
UTMD
Q4 25
11.16×
1.36×
Q3 25
1.47×
Q2 25
-0.25×
0.94×
Q1 25
-90.26×
1.47×
Q4 24
1.01×
Q3 24
1.38×
1.08×
Q2 24
-0.66×
0.80×
Q1 24
-4.32×
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons